Emergent BioSolutions Inc. (EBS) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Emergent BioSolutions Inc. (EBS) Bundle
Explore the financial future of Emergent BioSolutions Inc. (EBS) with our user-friendly DCF Calculator! Enter your projections for growth, margins, and expenses to calculate the intrinsic value of Emergent BioSolutions Inc. (EBS) and enhance your investment strategy.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,106.0 | 1,555.4 | 1,792.7 | 1,120.9 | 1,049.3 | 1,080.9 | 1,113.4 | 1,146.8 | 1,181.3 | 1,216.8 |
| Revenue Growth, % | 0 | 40.63 | 15.26 | -37.47 | -6.39 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 |
| EBITDA | 227.3 | 549.0 | 458.2 | -32.9 | -505.3 | 65.5 | 67.5 | 69.5 | 71.6 | 73.8 |
| EBITDA, % | 20.55 | 35.3 | 25.56 | -2.94 | -48.16 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 |
| Depreciation | 110.9 | 114.4 | 126.3 | 148.9 | 125.1 | 107.3 | 110.5 | 113.8 | 117.3 | 120.8 |
| Depreciation, % | 10.03 | 7.36 | 7.05 | 13.28 | 11.92 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 |
| EBIT | 116.4 | 434.6 | 331.9 | -181.8 | -630.4 | -41.8 | -43.0 | -44.3 | -45.6 | -47.0 |
| EBIT, % | 10.52 | 27.94 | 18.51 | -16.22 | -60.08 | -3.86 | -3.86 | -3.86 | -3.86 | -3.86 |
| Total Cash | 167.8 | 621.3 | 576.1 | 642.6 | 111.7 | 335.6 | 345.6 | 356.0 | 366.7 | 377.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 270.7 | 230.9 | 278.9 | 159.2 | 191.0 | 188.7 | 194.4 | 200.2 | 206.2 | 212.4 |
| Account Receivables, % | 24.48 | 14.85 | 15.56 | 14.2 | 18.2 | 17.46 | 17.46 | 17.46 | 17.46 | 17.46 |
| Inventories | 222.5 | 307.0 | 350.8 | 351.8 | 328.9 | 264.1 | 272.0 | 280.2 | 288.6 | 297.3 |
| Inventories, % | 20.12 | 19.74 | 19.57 | 31.39 | 31.34 | 24.43 | 24.43 | 24.43 | 24.43 | 24.43 |
| Accounts Payable | 94.8 | 136.1 | 128.9 | 103.5 | 112.2 | 96.1 | 99.0 | 101.9 | 105.0 | 108.1 |
| Accounts Payable, % | 8.57 | 8.75 | 7.19 | 9.23 | 10.69 | 8.89 | 8.89 | 8.89 | 8.89 | 8.89 |
| Capital Expenditure | -86.9 | -141.0 | -225.0 | -115.8 | -51.6 | -96.7 | -99.6 | -102.6 | -105.7 | -108.8 |
| Capital Expenditure, % | -7.86 | -9.07 | -12.55 | -10.33 | -4.92 | -8.94 | -8.94 | -8.94 | -8.94 | -8.94 |
| Tax Rate, % | -4.01 | -4.01 | -4.01 | -4.01 | -4.01 | -4.01 | -4.01 | -4.01 | -4.01 | -4.01 |
| EBITAT | 82.0 | 326.4 | 231.7 | -183.5 | -655.7 | -34.7 | -35.7 | -36.8 | -37.9 | -39.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -292.4 | 296.4 | 34.0 | -57.1 | -582.4 | 27.0 | -35.5 | -36.6 | -37.7 | -38.8 |
| WACC, % | 8.74 | 9.06 | 8.7 | 10.77 | 10.77 | 9.61 | 9.61 | 9.61 | 9.61 | 9.61 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -83.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -40 | |||||||||
| Terminal Value | -521 | |||||||||
| Present Terminal Value | -329 | |||||||||
| Enterprise Value | -412 | |||||||||
| Net Debt | 749 | |||||||||
| Equity Value | -1,161 | |||||||||
| Diluted Shares Outstanding, MM | 51 | |||||||||
| Equity Value Per Share | -22.67 |
What You Will Get
- Real Emergent BioSolutions Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Emergent BioSolutions' fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Comprehensive Data: Emergent BioSolutions Inc.’s (EBS) historical financial statements and detailed forecasts.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Analysis: Watch Emergent BioSolutions Inc.’s (EBS) intrinsic value update instantly.
- Intuitive Visuals: Dashboard charts illustrate valuation outcomes and essential metrics.
- Designed for Precision: A reliable tool for analysts, investors, and finance professionals.
How It Works
- Download: Obtain the pre-formatted Excel file featuring Emergent BioSolutions Inc. (EBS) financial data.
- Customize: Modify forecasts such as revenue growth, EBITDA %, and WACC to suit your analysis.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time as you make changes.
- Test Scenarios: Develop various projections and instantly compare different outcomes.
- Make Decisions: Leverage the valuation findings to inform your investment strategy.
Why Choose This Calculator for Emergent BioSolutions Inc. (EBS)?
- User-Friendly Interface: Perfectly crafted for both novice users and seasoned professionals.
- Customizable Inputs: Effortlessly adjust parameters to suit your specific analysis needs.
- Real-Time Feedback: Monitor immediate changes to Emergent BioSolutions' valuation as you tweak inputs.
- Preloaded Financial Data: Comes with Emergent BioSolutions' actual financial figures for swift evaluation.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive valuation models for analyzing portfolios in the biotech sector.
- Corporate Finance Teams: Assess valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation insights for Emergent BioSolutions Inc. (EBS) to clients.
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotech firms like Emergent BioSolutions Inc. (EBS) are valued in the marketplace.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations tailored for Emergent BioSolutions Inc. (EBS).
- Real-World Data: Emergent BioSolutions’ historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into the company's performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to Emergent BioSolutions Inc. (EBS).
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable insights.